MCMerve Cakir

Merve Cakir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merve Cakir has a total of 587 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Autism mutations rewire protein interaction networks to drive neurodevelopmental pathology

    by Belinda Wang, Rasika Vartak, Kelsey M. Hennick, Yefim Zaltsman, Zun Zar Chi Naing, Benjamin J. Polacco, Ali Bashir, Manon Eckhardt, Mehdi Bouhaddou, Jiewei Xu, et al.

    Systematic mapping of protein-protein interaction (PPI) networks and determining how causal mutations rewire them in autism spectrum disorder (ASD) provide a powerful framework for uncovering disease mechanisms and therapeutic opportunities. Using affinity purification–mass spectrometry, we systematically mapped PPIs for 100 high-confidence ASD genes, uncovering more than 1800 interactions. By assessing the impact of pathogenic missense mutations, leveraging AlphaFold, and validating key findings in human-derived model systems, we identified marked convergence onto shared protein complexes in the wild-type state and convergent PPI rewiring driven by independent mutations. For example, distinct patient-derived variants in FOXP1 disrupt its interactions with FOXP4, leading to changes in cortical neurogenesis and neural activity in brain organoids. Overall, these findings link genetic variation to protein networks and convergent neurodevelopmental dysfunction in ASD.


  • Open Access

    Genetic survey of biomarkers at early and mid-pregnancy identifies pregnancy-specialized immune regulation

    by Merve Cakir, Michela Traglia, Stacey Alexeeff, Jennifer L. Ames, Paul Ashwood, Luke P. Grosvenor, Erica P. Gunderson, Danielle H. J. Kim, Jane W. Liang, Yinge Qian, et al.

    Much remains unknown about the genetics of immune system changes during pregnancy. We used SNP data in a pregnancy cohort to genetically investigate 47 immune biomarkers at two timepoints, along with change between timepoints (Δ). We identified 19 biomarkers with significant SNP-based heritability and 34 with genome-wide significant signals, demonstrating genetic regulation. The same biomarkers measured in early- and mid-pregnancy shared about half of significant associations across timepoints, with enrichment for immune pathways. In contrast, Δ showed enrichment in transcription factors and developmental processes. About half of suggestive associations overlapped with non-pregnancy associations. However, these data leave a substantial fraction of potentially timepoint-specific and pregnancy-unique findings. Nearby genes were enriched for high expression in decidual cells at the maternal-fetal interface, reinforcing the novelty of our results. We additionally explored the relationship between immune genetic associations and prior GWAS of pregnancy complications. Overall, we present the first two-timepoint genetic study of immune profile in pregnancy.

  • Open Access

    Genetic survey of biomarkers across pregnancy identifies pregnancy-specialized immune regulation

    by Merve Cakir, Michela Traglia, Stacey Alexeeff, Jennifer L. Ames, Paul Ashwood, Luke P. Grosvenor, Erica P. Gunderson, Danielle Hj Kim, Jane W. Liang, Yinge Qian, et al.

    Much remains unknown about the genetics of immune system changes during pregnancy. We used SNP data in a pregnancy cohort to genetically investigate 47 immune biomarkers at two timepoints, along with change between timepoints (delta). We identified 19 biomarkers with significant SNP-based heritability and 34 with genome-wide significant signals, demonstrating genetic regulation. The same biomarkers measured in early- and mid-pregnancy shared about half of significant associations across timepoints, with enrichment for immune pathways. In contrast, delta showed enrichment in transcription factors and developmental processes. About half of suggestive associations overlapped with non-pregnancy associations. However, these data leave a substantial fraction of potentially timepoint-specific and pregnancy-unique findings. Nearby genes were enriched for placental expression, reinforcing the novelty of our results. We additionally explored the relationship between immune genetic associations and prior GWAS of pregnancy complications. Overall, we present the first multi-timepoint genetic study of immune profile in pregnancy.

  • Open Access

    Data from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Summary:The mapping of SARS-CoV-2 human protein–protein interactions by Gordon and colleagues revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host–virus interface of SARS-CoV-2 to enable cancer biologists to apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.

  • Open Access

    Table S1 from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Cancer drugs targeting the identified virus-host protein-protein interactions of SARS-CoV-2

  • Open Access

    Table S1 from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Cancer drugs targeting the identified virus-host protein-protein interactions of SARS-CoV-2

  • Open Access

    Data from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Summary:The mapping of SARS-CoV-2 human protein–protein interactions by Gordon and colleagues revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host–virus interface of SARS-CoV-2 to enable cancer biologists to apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.

  • Top Cited Papers
    Open Access

    Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

    by David E. Gordon, Joseph Hiatt, Mehdi Bouhaddou, Veronica V. Rezelj, Svenja Ulferts, Hannes Braberg, Alexander S. Jureka, Kirsten Obernier, Jeffrey Z. Guo, Jyoti Batra, et al.

    How lethal coronaviruses engage hosts: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is closely related to the deadly coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). Considerable efforts are focused on developing treatments, and therapies that work across coronaviruses would be particularly valuable. Shedding light on the host factors hijacked by the viruses, Gordon et al. mapped the interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV; analyzed the localization of viral proteins in human cells; and used genetic screening to identify host factors that either enhance or inhibit viral infection. For a subset of the interactions essential for the virus life cycle, the authors determined the cryo–electron microscopy structures and mined patient data to understand how targeting host factors may be relevant to clinical outcomes. Science , this issue p. eabe9403


  • Top Cited Papers

    The Global Phosphorylation Landscape of SARS-CoV-2 Infection

    by Mehdi Bouhaddou, Danish Memon, Bjoern Meyer, Kris M. White, Veronica V. Rezelj, Miguel Correa Marrero, Benjamin J. Polacco, James E. Melnyk, Svenja Ulferts, Robyn M. Kaake, et al.


  • Open Access

    The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Summary: The mapping of SARS-CoV-2 human protein–protein interactions by Gordon and colleagues revealed druggable targets that are hijacked by the virus. Here, we highlight several oncogenic pathways identified at the host–virus interface of SARS-CoV-2 to enable cancer biologists to apply their knowledge for rapid drug repurposing to treat COVID-19, and help inform the response to potential long-term complications of the disease.